ProjectMK-3475 Prot. 630
Basic data
Title:
MK-3475 Prot. 630
Duration:
01/07/2019 to 30/09/2021
Abstract / short description:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma
(LA cSCC) (KEYNOTE-630)
(LA cSCC) (KEYNOTE-630)
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
München, Bayern, Germany